A ROUND THE world, dealmaking is in a rut. A combination of higher interest rates, geopolitical tensions and economic uncertainty has put a hold on joint ventures, mergers and acquisitions. One ...
An Israeli company that has a U.S. headquarters in Waltham said Monday it has received approval for a new drug for blood cancer. Biopharmaceutical company BioLineRx Ltd. (Nasdaq: BLRX) said the U ...
The Cancer Drugs Market is estimated to be valued at US$ 143.9 Bn in 2022 and is expected to exhibit a CAGR of 7.60% over the ...
The US Food and Drug Administration (FDA) has increased its collaboration with cancer drug manufacturers in a bid to overcome the country’s ongoing drug shortage problem and reduce impacts on patients ...
Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Wednesday the U.S. Food and Drug Administration (FDA) ...
A groundbreaking anticancer treatment technology that selectively targets cancer cell lysosomes and overcomes drug resistance has been developed by Professor Ja-Hyoung Ryu and his research team in the ...
Sept 15 (Reuters) - (This Sept. 15 story has been corrected show that momelotinib is approved for patients regardless of prior myelofibrosis therapy, not just for patients previously treated ...
An Israeli company that has a U.S. headquarters in Waltham said Monday it has received approval for a new drug for blood cancer. Biopharmaceutical company BioLineRx Ltd. said the U.S. Food and ...
FDA reduced the therapeutic equivalence rating for Accord Healthcare's tacrolimus oral capsules due to safety concerns. The generic is still approved and allowed to be prescribed.
A Food and Drug Administration advisory panel on Tuesday unanimously concluded that oral phenylephrine, the decongestant found in many common cold medications, is ineffective. Phenylephrine is ...
Phenylephrine, a popular ingredient in many over-the-counter allergy and cold medicines, is ineffective in tablet form, an independent advisory committee to the US Food and Drug Administration ...
(Reuters) - (This Sept. 15 story has been corrected show that momelotinib is approved for patients regardless of prior myelofibrosis therapy, not just for patients previously treated with JAK ...
